🇺🇸 FDA
Pipeline program

Anti-HER2 CAR-T

TMMU-BTC-005

Phase 2 mab terminated

Quick answer

Anti-HER2 CAR-T for Breast Cancer is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Breast Cancer
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials